Douglas Forsyth
Director · Inhibrx Biosciences, Inc.
- 2025
- Sep 18, 2026
- 4
Summary
Latest filing:
Douglas Forsyth is Director of Inhibrx Biosciences, Inc. (INBX). 4 SEC Form 4 filings on record going back to 2025, most recently on 18 September 2026. Most recent open-market trade: bought $287K of INBX on 8 September 2026. Lifetime open-market purchases: $287K.
Recent transactions
1The latest SEC Form 4 transaction reported by Douglas Forsyth.
Trading pattern
InsiderAlpha's records for Douglas Forsyth go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $287K (1 buy totaling $287K). The largest single buy on record is $287K of INBX in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Douglas Forsyth files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Mark Lappe - $3.64M in INBX purchases and sales in the last 12 months
- Jon Faiz Kayyem - $1.57M in INBX purchases and sales in the last 12 months
- Kimberly Manhard - $279K in INBX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Douglas Forsyth?
Douglas Forsyth is a corporate insider, tracked as Director of Inhibrx Biosciences, Inc. (INBX). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Douglas Forsyth submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Douglas Forsyth been buying or selling stock?
Recorded transactions: 1 open-market purchase ($287K) and 0 open-market sales across all tracked filings.